Single Cell Analysis Systems for Therapeutic Discovery Name, Date and Conference/Client Title 3rd February 2016.

COMPANY INTRODUCTION Sphere Fluidics (SF) is an established Life Sciences Tools spin-out from the University of Cambridge focussing on Single Cell Analysis. Originally commercialised Research Instruments and Consumables (c. 40 products) and R&D Collaborations to generate rapid income and learn the market. Strategy has evolved to now developing Industrial Systems that enable rapid ultra-high-throughput discovery of therapeutics from single cells (e.g. Cyto-Mine®). IP Protection: 54 patents and 2 Trademarks created with over £12M of grants and funding. Raised £4M in funding to date, income-generating and now raising ~£6M (£4.6M already committed; Pre-money of £10M).

Core Technology: Encapsulation and Assay of Single Cells in Picodroplets Name, Date and Conference/Client Title

PICODROPLETS – MINIATURE “TEST TUBES” FOR SINGLE CELLS Novel microfluidics can produce, manipulate, analyse, sort, fuse, split, retrieve and dispense millions of picodroplets per biochip per day. Picodroplets are small volume (pl-nl) aqueous droplets in oil made at rates of > 100,000 per min. They enable testing of trapped, secreted molecules (e.g. antibodies). Picodroplets are stabilised using novel biocompatible surfactants and are useful for many weeks. A microfluidic biochip (a few cms in size) Oil Cells Picodroplets containing single cells Stored picodroplets

Cell growth (e.g. T-cells) EXAMPLE PICODROPLET OPERATIONS Cell encapsulation Sorting Spacing Picodroplet splitting Cell growth (e.g. T-cells) Fusion Cell division occurs within 48 hours

SF TECHNOLOGY: FEATURES AND BENEFITS High-throughput: can perform millions of single cell tests per biochip and isolate rare variants from a vast population. Miniaturised: can save up to £0.5M per R&D program (e.g. GSK). Enabling: Screen entire libraries significantly improving rates of finding unique variants or high expressors. Picodroplet fusion: enables inline co-incubation and novel functional assays – impossible to do by conventional techniques. Picodroplet splitting: facilitates mass spectrometry and other analyses allowing retrieval of “hit” replicates - gives > 20-fold faster analysis.

Target markets Name, Date and Conference/Client Title

PRIORITISED MARKETS (ADDRESSABLE) - A £BILLION 1) Biopharmaceutical Discovery & Development (£214 MM growing at 10% p.a.). 2) Synthetic Biology - Bioprocessing (£135 MM growing at 42% p.a.). 3) Stem Cell Engineering, Isolation and Analysis (£580 MM growing at 14% p.a.). 4) Single Cell Disease Research (Infectious Diseases: £60 MM growing at 6% p.a.). 5) Single Cell Diagnostics and Prognostics - Cancer Market (Total): £20 billion growing at 15% p.a.

Cyto-Mine®: Next Generation Platform for Biopharmaceutical Discovery and Development Name, Date and Conference/Client Title

CYTO-MINE® (THE INDUSTRIAL SYSTEM) OVERVIEW The Single Cell Analysis & Monoclonality Assurance System: Single cell analysis, cloning and isolation techniques are critical for biopharmaceutical discovery and development. Conventional techniques offer partial solutions performing some of the following: high-throughput screening, protein secretion assays, rapid cell sorting, single cell dispensing to microplates and monoclonality verification. Cyto-Mine® will be the world’s first integrated device specifically designed to automatically perform all of these functions in a single system.

COMPETITIVE ADVANTAGE OF CYTO-MINE®

PROJECTED SALES: CYTO-MINE® PRIMARY MARKET Cyto-Mine®: An integrated, high-throughput single cell analysis platform using optical detection. Primary Market: Biopharmaceuticals Addressable User Base: 480 international Biopharma firms, CROs and Core Labs Addressable Market: £214 MM.

PROJECTED SALES: CYTO-MINE® IN ALL 5 MARKETS

Financial Projections Name, Date and Conference/Client Title

FINANCIAL PROJECTIONS Cyto-Mine® Units Sold: 0 3 15 27 41 44 Other Instruments Sold: 0 4 0 0 15 23

USE OF FUNDS  Raising circa. £6 M of investment (Pre-money: £10 M; £4.6 M already committed), ~£1.4M investment opportunity to: Commercialise the world‘s first integrated, single cell analysis system (Cyto-Mine®) in Biopharmaceutical Discovery and Devt. Position Cyto-Mine® technology into other new markets. Progress development and sales of the ESI-Mine™ system. Enable expansion of facility, the commercial and technical teams. Exit is by Trade Sale within the next 3 - 4 years to a global, Life Sciences company for £100M - £200M. Full business plan and due diligence materials available.

THANK YOU Investor Meetings: Ongoing. Key Contact: Dr. Frank F. Craig CEO, Sphere Fluidics Ltd Tel: +44 7805 659566 / +44 1223 804201 E-mail: Frank.Craig@spherefluidics.com